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Introduction: The application of herbal plants because of their lower side-effects has been 
increasing in recent years. 
Objectives: we aimed to study the effects of hydro-alcoholic extract of Momordica charantia 
(bitter melon) on liver function and tissue structure in mice.
Materials and Methods: This study was conducted on 70 male mice which were randomly 
designated into 7 groups of 10 and were injected with single doses of 0, 100, 500, 1000, 
2000 and 4000 mg/kg and multiple daily dose of 500 mg/kg for 7 days, intraperitoneally. 
Finally, liver tissues were taken out for histological examinations. Serum samples were assayed 
for liver enzymes activities of alkaline phosphatase, aspartate aminotransferase and alanine 
aminotransferase. Also the antioxidant activity of blood and bitter melon were measured. 
Subsequently, data were analyzed by analysis of variance (ANOVA) and Bonferroni tests using 
Stata software. 
Results: The results of the present study showed that a single dose of Momordica charantia 
fruit extract at doses up to 4000 mg/kg extract does not significant adverse effects on the liver 
enzymes and tissue structure.
Conclusion: Using this drug for short time and low dose has not toxicity effects on liver enzymes 
activity and tissue structure, hence, it is safe in this range of doses.
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Introduction 
Since ancient times the use of medicinal 
plants has been common in the treatment 
of many diseases (1). But, some constituents 
of these herbs may lead to severe and on oc-
casion fatal poisoning. Hence we are today 
faced with case reports of toxic herbs, con-
stantly (2). A lot of herbal products are used 
to reduce blood sugar in different cultures, 
among them Momordica charantia is the 
most common medical plant (3).
Bitter melon belongs to the Cucurbitace-
ae family, Momordica genus and it is also 
known as Bitter ground in England, Karela 
in India, Paharkia in Tamil, Pinyin in China 
and in Malaysia (4).
It has various effects such as anti-diabetic, 
anti-viral, anti-tumor, anti-ulcer, anti-in-
flammatory, lowering cholesterol, lower-
ing triglycerides, blood pressure, immune 
stimulant, insect repellent, prevention of 
pregnancy, antimalarial, anti-eczema, prop-
erty menstrual stimulant, anti-pneumonia, 
Core tip 
Administration of Momordica charantia for 
short time and low dose has not toxicity 
effects on liver enzymes activity and tissue 
structure, hence, it is safe in this range of 
doses.
anti-rheumatoid arthritis, anti-scabies, an-
ti-psoriasis, and cytotoxic properties (5).
Hypoglycemic activity is one of the most 
obvious medicinal properties of this herb so 
that all parts of the plant such as fruits, seeds, 
leaves and roots have this feature and because 
of the long-term history of use, this plant 
is known as herbal insulin. Over the years 
several mechanisms have been introduced 
to explain the hypoglycemic activity of this 
drug. For example, one of these proposed 
mechanisms is inhibition of glucose absorp-
tion in intestinal tract by drugs (6). Other 
evidences suggest that Momordica charantia 
reduces gluconeogenesis, increases glycogen 
synthesis in the liver and also rises glucose 
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oxidation in peripheral erythrocytes and fat cells (7).
Some studies have reported that Momordica charantia in-
creases the secretion of insulin from the pancreas. Hence, 
this hypothesis was created that Momordica charantia ex-
tract increases the production of beta cells in the pancre-
as, although this mechanism has not been confirmed by 
studies (8). 
Objectives
There are some unofficial reports denoting the possible 
liver toxicity of this plant. While, there are not sufficient 
published reports about side effects of bitter melon, we in-
tended to investigate the effects of this herbal medicine on 
liver enzymes activity and histological changes.
 
Materials and Methods
Momordica charantia fruits were obtained from India and 
approved by expert botanist in Medical Plants Research 
Center of Shahrekord University of Medical Science, 
Shahrekord, Iran.
Extraction process
Hydro-alcoholic extract of Momordica charantia was pre-
pared by percolation method with 95% ethanol, followed 
by steam evaporation, after that, five different concentra-
tions of extract were prepared. 
Phytochemical analysis
Total flavonoids content was estimated by aluminum 
chloride colorimetric method. The standard solutions of 
routine with concentrations of 25, 50, 100, 250 and 500 
ppm from 60% methanol was prepared, then 1 mL of each 
solution was transferred to test tubes and 1 mL solution of 
aluminum chloride 2% and then 6 mL of potassium ace-
tate 5% was added to the solution and after 40 minutes the 
absorbance was measured at 415 nm (9).
Measurement of total phenolic content
Total phenolic content was determined by folin-ciocalteu 
reagent method and the absorbance was measured at 760 
nm. Total phenolic content in terms mg/g of extract was 
calculated (10).
Antioxidant activity assays
Β-carotene/linoleic acid-coupled oxidation reaction
A solution of β-carotene was prepared by liquefying 2 mg 
in 10 mL of chloroform. Then 0.02 mL of linoleic acid 
and 0.2 mL of tween 40 was added, and the mixture was 
remained at 20°C for 15 minutes. After dehydration of 
the chloroform in a rotary evaporator at 40°C, 50 mL of 
oxygen-saturated distilled water at 25°C was added and 
the mixture was vortexed strongly (1 minute) to form 
an emulsion (β-carotene/linoleic acid emulsion). The re-
quired wells were charged (of a 96-well microtiter plate) 
with each different amount of samples and 100 μL of emul-
sion per well. The microplate was located on a horizontal 
shaker and shaken at 100 rpm (during 1 minute). A con-
trol sample was also arranged similarly. Absorbance mea-
surements (470 nm) at t = 0 minute were made after incu-
bation at 50°C during 120 minutes. All experiments were 
done in triplicate. Antioxidant activity was mentioned as 
the percent of inhibition with regard to the control sample 
and calculated as follows:
AA=100[1-A0-At1] /[A0-Atc].
where SA0 and CA0 are the absorbance values of the sample 
and the control defined at 0 minute; the SAt and CAt were 
the absorbance values of test sample and control measured 
after 120 minutes. BHT was used as positive control (11).
Animal and treatment
Seventy male db/db mice weighing 25-30 g and 3 weeks 
old were distributed into seven groups with 10 animals 
randomly in each group as follows: 
Group 1: control group (without drug)
Group 2: obtained at 100 mg/kg extract as a single dose. 
Group 3: received at 500 mg/kg extract as a single dose. 
Group 4: gained 1000 mg/kg extract as a single dose. 
Group5: received 2000 mg/kg extract as a single dose. 
Group 6: obtained 4000 mg/kg extract as a single dose. 
Group 7: received 500 mg/kg/day extract for one week.
All of the mice were maintained on a 12-hour light/dark 
cycle. All protocols for animal use were approved by the 
animal care committee of Shahrekord University of Med-
ical Sciences animal care. All the experiments were done 
after one week in order for the mice to become accus-
tomed to the new environment and they could freely ac-
cess water and food (12). After one week on the eighth day 
various doses of the extract was injected intraperitoneally 
to mice. The mice were cared for 72 hours and then they 
were anesthetized and blood samples were stored in tubes 
for biochemical parameters estimation (13). Then blood 
samples were centrifuged at 3500 rpm for 15 minutes to 
evaluate serum liver enzymes. Liver enzymes were mea-
sured with enzymatic method (Pars Azmoon kit) by Auto-
matic Analyzer 902 (Hitachi, Germany).
Ferric reducing ability 
Ferric reducing ability of plasma (FRAP) reagent was 
mixed with 90 μL of distilled water and 30 μL of test sam-
ple solutions. The reaction mixture was then incubated 
at 37°C for 10 minutes and absorbance was recorded at 
593 nm, using a spectrophotometer (uv3100 Shimadzu, 
Japan). The concentrations of FeSO4 were in turn plotted 
against concentrations of the standard antioxidants (14). 
Histological study 
After animals were euthanized by ether, liver tissues were 
collected and put into 10% buffered formalin for 48 hours. 
Subsequently, organs were embedded within paraffin. 
Solid sections of 5 μm thickness were made using a mi-
crotome. The sections were stained with hematoxylin and 
eosin (H&E) and then observed by light microscopy for 
histopathological examination (15).
Ethical issues 
The research followed the tenets of the Declaration of Hel-
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sinki. The research was approved by ethical committee of 
Shahrekord University of Medical Sciences. Prior to the 
experiment, the protocols were confirmed to be in accor-
dance with the guidelines of Animal Ethics Committee of 
Shahrekord University of Medical Sciences.
Statistical analysis
Data were analyzed by analysis of variance (ANOVA) and 
chi-square tests using SPSS software. P < 0.05 was consid-
ered significant for all data.
Results
Antioxidant capacity of bitter melon (percent inhibition 
of peroxidation in linoleic acid production) was 68%. The 
amount of flavonoids was 54 mL/μg, flavonols 45 mL/μg 
and phenolic content 413 mL/μg in the extract.
 
Antioxidant capacity of blood
Antioxidant capacity of blood was 568 µmol/L before the 
study. After the intervention the blood antioxidant capaci-
ties in groups were as follows:
Group 1: (control group) 564 µmol/L; group 2: 1108 
µmol/L; group 3: 741 µmol/L; group 4: 553 µmol/L; group 
5: 703 µmol/L; group 6: 624 µmol/L; group 7: 436 µmol/L.
Effect of different doses of Momordica charantia on 
liver enzymes activity
There were no significant difference of alkaline phos-
phatase (ALP), aspartate aminotransferase (SGOT), al-
anine aminotransferase (SGPT) activity between groups 
(P > 0.05; Table 1).
Effects of different doses of Momordica charantia on 
liver histology
Histological examination of the liver showed no patholog-
ic findings and there was not significant different between 
liver tissue in control group and other treatment groups 
(P > 0.05).
Discussion
In this study, 70 mice were divided into 7 groups and were 
treated with different doses of Momordica charantia ex-
tract. The smallest dose was 100 mg/kg, and the greatest 
was 4000 mg/kg. Also, a group treated for one week 500 
mg/kg extract. In this study, liver enzymes activity includ-
ing ALP, SGPT and SGOT was measured. During the in-
tervention, liver enzymes were not significantly different 
between the control group and groups treated with extract.
As well, there were not changes in histology of liver tissue 
in our study and there was not difference between treated 
groups and control group. 
The results in our study were in agreement with the results 
of another study which was carried out on the effects of 
Momordica charantia on key hepatic enzymes and indicat-
ed that this valuable plant contain hepatotoxin capable of 
causing cellular damage but at molecular level without any 
significant histopatological change. While in many other 
investigations effects of Momordica charantia on kidney 
were confirmed because not only kidney is one of the most 
affected organs by diabetes but also in many researches the 
anti-diabetic properties of this worthy herbal drug has 
been proved currently like lots of other medicinal plant.
A report about the effect of Momordica charantia on di-
abetic mice showed that due to diabetes extra space be-
tween hepatic sinusoids of liver disappeared after treat-
ing with extract. The extract of bitter melon can protect 
damage tissue liver (16). Also in the study conducted by 
Nazrul-Hakim  et al liver pathology was examined and 
they observed a small amount of congestion and also 
found that there were no significant differences between 
control and other groups (17). Subsequently, the results of 
the present study remarkably showed that a single dose of 
Momordica charantia fruit extract at doses up to 4000 mg/
kg extract does have not significant adverse effects on the 
liver contrary to effect on kidney structure and tissue. Be-
cause of antioxidant activity of this medicinal plant and 
also its anti-diabetic characteristics we strongly recom-
mend more research about its impact on all organs and 
tissues involved in diabetes.
Conclusion
Momordica charantia extract and low dose had not toxicity 
effects on liver enzymes activity and tissue for short time 
so long term treatment for patients with liver abnormal-
ities should be checked regularly and if it has disrupting 
drug should be discontinued.
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Table 1. Comparison mean of liver enzyme activity in the study groups
Groups SGOT (mg/dL) SGPT (mg/dL) ALP (mg/dL)
(Control) 165.5 ± 51 90 ± 70 200 ± 95
(100 mg/kg) 196 ± 91 97.8 ± 68 206 ± 71
(500 mg/kg) 143 ± 57 67.7 ± 45 243 ± 108
(1000 mg/kg) 199 ± 92 77 ± 40 190 ± 110
(2000 mg/kg) 173 ± 130 49.5 ± 28 159 ± 62
(4000 mg/kg) 206 ± 38 88 ± 67 192 ± 99
(500 mg/kg) 180 ± 63 85.7 ± 40 223 ± 49
Total mean 180.8 ± 76 80.6 ± 54 204.7 ± 88
Data are shown as the Mean ± SEM, (n = 7, P < 0.05).
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